Three years of experience:the Italian registry and safety data update.

Giovanni Savettieri, Mancardi, Laroni, Carlo Piccinni, Laura Periotto, Marisa De Rosa, Rosamaria Iommelli, Drago, Patrizia Popoli, Tomino, Tomino, Anna Covezzoli, Provinciali, Tomino, Nicola Montanaro, Nicola Vanacore, Clara Milanese, Pozzilli, Giovanni Savettieri, Antonio BertolottoMarrosu, Tola, Luigi M.E. Grimaldi, Provinciali, Gioacchino Tedeschi, Roberto D'Alessandro, Maria Pia Amato, Comi, Rossi

    Risultato della ricerca: Articlepeer review

    26 Citazioni (Scopus)

    Abstract

    At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%.Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability was documented.
    Lingua originaleEnglish
    pagine (da-a)295-297
    Numero di pagine3
    RivistaNeurological Sciences
    Volume31
    Stato di pubblicazionePublished - 2011

    All Science Journal Classification (ASJC) codes

    • Dermatology
    • Clinical Neurology
    • Psychiatry and Mental health

    Fingerprint Entra nei temi di ricerca di 'Three years of experience:the Italian registry and safety data update.'. Insieme formano una fingerprint unica.

    Cita questo